nach oben

Current Sexual Health Reports

Erschienen in:

07.06.2023

Persistent Genital Arousal Disorder/Genitopelvic Dysesthesia: Review of the Current State of the Treatment Literature and Future Directions in Treatment

verfasst von: M. E. Mulroy, C. F. Pukall

Erschienen in: Current Sexual Health Reports | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of the present paper was to briefly review the diagnostic criteria for persistent genital arousal disorder/genitopelvic dysesthesia (PGAD/GPD), its symptom characteristics and psychosocial impacts, proposed etiologies, and assessment, and to delve into the treatment literature to evaluate the current state of the literature. The review sought to broadly evaluate the degree of support currently present for various management strategies and to identify future directions for PGAD/GPD treatment research.

Recent Findings

Research on PGAD/GPD treatments remains limited at present, consisting mainly of case studies, chart reviews, and a small number of preliminary treatment outcome studies with small sample sizes.

Summary

Because of the limited treatment literature in PGAD/GPD, our recommendations related to the future directions of PGAD/GPD treatment are informed by the treatment literature of genitopelvic dysesthesias characterized by pain (e.g., vulvodynia). The genitopelvic pain literature supports the efficacy of a variety of treatment options, particularly psychotherapy (including cognitive behavioral therapy and mindfulness) and pelvic floor physical therapy, suggesting these to be valuable non-medical treatment avenues for future PGAD/GPD research.

•• Goldstein I, Komisaruk BR, Pukall CF, Kim NN, Goldstein AT, Goldstein SW, et al. International Society for the Study of Women’s Sexual Health (ISSWSH) review of epidemiology and pathophysiology, and a consensus nomenclature and process of care for the management of persistent genital arousal disorder/genito-pelvic dysesthesia (PGAD/GPD). J Sex Med. 2021:18(4):665–97. This paper presents the most recent diagnostic criteria for PGAD/GPD and presents a treatment algorithm based on available evidence.

Jackowich R, Pink L, Gordon A, Poirier É, Pukall CF. Symptom characteristics and medical history of an online sample of women who experience symptoms of persistent genital arousal. J Sex Marital Ther. 2018;44(2):111–26.CrossRefPubMed

Jackowich RA, Pukall CF. Prevalence of persistent genital arousal disorder in 2 North American samples. J Sex Med. 2020;17:2408–16.CrossRefPubMed

Jackowich RA, Boyer SC, Bienias S, Chamberlain S, Pukall CF. Healthcare experiences of individuals with persistent genital arousal disorder/genito-pelvic dysesthesia. Sexual Medicine. 2021;9(3):100335–100335.CrossRefPubMedPubMedCentral

World Health Organization. International classification of diseases, Eleventh Revision (ICD-11). Zurich: World Health Organization (WHO); 2019/2021. https://icd.who.int/browse11.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association; 2017. https://doi.org/10.1176/appi.books.9780890425787

•• Pukall CF, Goldmeier D. Persistent genital arousal disorder. In: Binik YM, Hall K, editors. Principles and practice of sex therapy. 6th ed. 6th ed. New York: Guilford Press:2020. p. 488–503. Chapter detailing assessment and treatment strategies for PGAD/GPD for clinicians.

Parish SJ, Goldstein AT, Goldstein SW, Goldstein I, Pfaus J, Clayton AH, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—part II. J Sex Med. 2016;13(12):1888–906.CrossRefPubMed

Jackowich RA, Pink L, Gordon A, Poirier É, Pukall CF. An online cross-sectional comparison of women with symptoms of persistent genital arousal, painful persistent genital arousal, and chronic vulvar pain. J Sex Med. 2018;15(4):558–67.CrossRefPubMed

10.

Oaklander AL, Sharma S, Kessler K, Price BH. Persistent genital arousal disorder: a special sense neuropathy. Pain reports. 2020;5(1):e801–e801.CrossRefPubMedPubMedCentral

11.

Waldinger MD, Schweitzer DH. Persistent Genital Arousal Disorder in 18 Dutch women: part II—a syndrome clustered with restless legs and overactive bladder. J Sex Med. 2009;6(2):482–97.CrossRefPubMed

12.

Waldinger MD, de Lint GJ, Venema PL, et al. Successful transcutaneous electrical nerve stimulation in two women with restless genital syndrome: the role of A-delta and C-nerve fibers. J Sex Med. 2010;7:1190–9.CrossRefPubMed

13.

Waldinger MD, Venema PL, Van Gils APG, Schutter EMJ, Schweitzer DH. Restless genital syndrome before and after clitoridectomy for spontaneous orgasms: a case report. J Sex Med. 2010;7(2pt2):1029–34.

14.

Goldstein I. Persistent genital arousal disorder—update on the monster sexual dysfunction. J Sex Med. 2013;10(10):2357–8.CrossRefPubMed

15.

Jackowich RA, Pink L, Gordon A, Pukall CF. Persistent genital arousal disorder: a review of its conceptualizations, potential origins, impact, and treatment. Sex Med Rev. 2016;4(4):329–42.CrossRefPubMed

16.

Jackowich RA, Poirier É, Pukall CF. A comparison of medical comorbidities, psychosocial, and sexual well-being in an online cross-sectional sample of women experiencing persistent genital arousal symptoms and a control group. J Sex Med. 2020;17(1):69–82.CrossRefPubMed

17.

Mooney KM, Poirier É, Pukall CF. Persistent genital arousal in relationships: A comparison of relationship, sexual, and psychological well-being. J Sex Med. 2021;19(2):234–48.CrossRefPubMed

18.

Leiblum S, Seehuus M, Goldmeier D, Brown C. Psychological, medical, and pharmacological correlates of persistent genital arousal disorder. J Sex Med. 2007;4(5):1358–66.CrossRefPubMed

19.

Myers M, Romanello J, Nico E, Sussman R, Marantidis J, Rubin R. Reduced satisfaction and increased recurrence after lysis procedure for clitoral adhesions in patients with Persistent Genital Arousal Disorder. J Sex Med. 2022;19(8):S20–S20.CrossRef

20.

Dallagiacoma S, Flora G, Ferrone S, Parodi F, Federico A. Tarlov’s cyst as an underestimated cause of persistent genital arousal disorder: a case report and review. Neurol Sci. 2020;41(11):3337–9.CrossRefPubMed

21.

Tannenbaum J, Greenberg J, Raheem O, Hellstrom W. Hormonal imbalances association to Persistent Genital Arousal Disorder in females. J Sex Med. 2022;19(4):S105.CrossRef

22.

Suwarno S, Vedula S, Shah N, Artounian K, Petty A. Lamotrigine-induced persistent genital arousal disorder and a potential treatment. J Sex Marital Ther. 2022: ahead-of-print(ahead-of-print):1–3.

23.

Facelle TM, Sadeghi-Nejad H, Goldmeier D. Persistent genital arousal disorder: characterization, etiology, and management. J Sex Med. 2013;10(2):439–50.CrossRefPubMed

24.

Anzellotti F, Franciotti R, Bonanni L, Tamburro G, Perrucci MG, Thoman A, et al. Persistent genital arousal disorder associated with functional hyperconnectivity of an epileptic focus. Neuroscience. 2010;167:88–96. https://doi.org/10.1016/j.neuroscience.2010.01.050.CrossRefPubMed

25.

Leiblum SR, Chivers ML. Normal and persistent genital arousal in women: new perspectives. J Sex Marital Ther. 2007;33:357–73.CrossRefPubMed

26.

Yero SA, McKinney T, Petrides G, Goldstein I, Kellner CH. Successful use of electroconvulsive therapy in 2 cases of persistent sexual arousal syndrome and bipolar disorder. J ECT. 2006;22(4):274–5.CrossRefPubMed

27.

Leiblum SR, Goldmeier D. Persistent genital arousal disorder in women: case reports of association with anti-depressant usage and withdrawal. J Sex Marital Ther. 2008;34(2):150–9.CrossRefPubMed

28.

Leiblum S, Brown C, Wan J, Rawlinson L. Persistent sexual arousal syndrome: a descriptive study. J Sex Med. 2005;2(3):331–7.CrossRefPubMed

29.

• Pukall CF, Komisaruk B, Goldstein I. Persistent genital arousal disorder. In: Y. Reisman et al., editors. Textbook of Rare Sexual Medicine Conditions. Switzerland: Springer Nature:2022. p. 37–49. Chapter summarizing the assessment, diagnosis, and treatment of PGAD/GPD and detailing the regions implicated in PGAD/GPD symptoms.

30.

Kim C, Blevins J, Goldstein S, Komisaruk B, Goldstein I. neurogenic persistent genital arousal disorder (PGAD) secondary to radiculopathy of sacral spinal nerve roots (SSNR): treatment outcomes following minimally invasive spine surgery (MISS). J Sex Med. 2020;17(1):S2–S2.CrossRef

31.

Feigenbaum F, Boone K. Persistent genital arousal disorder caused by spinal meningeal cysts in the sacrum; successful neurosurgical treatment. Obst Gynecol. 2016;126:839–43.CrossRef

32.

Aerts L. Successful management of PGAD and clitorodynia caused by a closed compartment syndrome. J Sex Med. 2016;13:S205–6.CrossRef

33.

Klifto K, Dellon AL. Persistent genital arousal disorder: treatment by neurolysis of dorsal branch of pudendal nerve. Microsurgery. 2020;40:160–6. https://doi.org/10.1002/micr.30464.CrossRefPubMed

34.

Uloko M, Yih J, Hartzell-Cushanick R, et al. Neuroproliferative vestibulodynia as a cause of persistent genital arousal disorder: a first-ever case series. J Sex Med 2021;(in press).

35.

Yildirim EA, Yildirim MH, Carpar E, Sarac I. Clomipramine trial for treatment-resistant genital arousal disorder: a case series. J Psychosomatic Obstetrics and Gynecology. 2017;38:260–7. https://doi.org/10.1080/0167482X.2017.1296427.CrossRef

36.

de Magalahes FJC, Kumar MT. Persistent genital arousal disorder following selective serotonin reuptake inhibitor cessation. J Clin Psychopharmacol. 2015;35:352–4. https://doi.org/10.1097/JCP.0000000000000318.CrossRef

37.

Philippsohn S, Kruger THC. Persistent genital arousal disorder: successful treatment with duloxetine and pregabalin in two cases. J Sex Med. 2012;9:213–7. https://doi.org/10.1111/j.1743-6109.2011.02518.x.CrossRefPubMed

38.

Deka K, Dua N, Kakoty M, Ahmed R. Persistent genital arousal disorder: successful treatment with leuprolide (antiandrogen). Indian Journal of Psychiatry. 2015;57:326–8. https://doi.org/10.4103/0019-5545.166633.CrossRefPubMedPubMedCentral

39.

Raj R, Bhagat N. Pramipexole with leuprolide: a treatment strategy for PGAD. Int J Basic Clin Pharmacol. 2017;6(7):1828–1832. https://doi.org/10.18203/2319-2003.ijbcp20172757.CrossRef

40.

Wylie K, Levin R, Hallam-Jones R, Goddard A. Sleep exacerbation of persistent sexual arousal syndrome in postmenopausal women. J Sex Med. 2006;3:296–302. https://doi.org/10.1111/j.1743-6109.2005.00167.x.CrossRefPubMed

41.

Lynn BK, Grabenhorst C, Lomisaruk BR, Goldstein I, Pfaus J. The use of pramipexole to treat persistent genital arousal disorder: a case report. Sexual Medicine. 2021;9:100372. https://doi.org/10.1016/j.esxm.2021.100372.CrossRefPubMedPubMedCentral

42.

King SA, Goldstein I, Pfaus J. 020 Mechanism of action and preliminary clinical experience with zolpidem, a non-benzodiazepine indirect GABA a receptor agonist, for symptomatic treatment of persistent genital arousal disorder (PGAD). J Sex Med. 2016;13(6):S247–8.CrossRef

43.

Goldstein I, Cataldo L, Komisaruk BR, Pfaus J. 409 Treatment of persistent genital arousal disorder (PGAD) with zolpidem, a non-benzodiazepine indirect GABA a receptor agonist: mechanism of action and preliminary clinical experience. J Sex Med. 2017;14(1):S124–S125. https://doi.org/10.1016/j.jsxm.2016.11.288.CrossRef

44.

Gaines N, Odom BD, Killinger KA, Peter KM. Pudendal neuromodulation as a treatment for persistent genital arousal disorder – a case series. Female Pelvic Med Reconstr Surg. 2018;24:e1-5. https://doi.org/10.1097/SPV.0000000000000435.CrossRefPubMed

45.

McMullen R, Agarwal S. Persistent genital arousal disorder – case report of symptomatic relief of symptoms with transcranial magnetic stimulation. J ECT. 2016;32:e9-10. https://doi.org/10.1097/YCT.0000000000000299.CrossRefPubMed

46.

Waldinger MD, Venema PL, van Gils APG, de Lint GJ, Schweitzer DH. Stronger evidence for small fiber sensory neuropathy in restless genital syndrome: two case reports in males. J Sex Med. 2011;8:325–30. https://doi.org/10.1111/j.1743-6109.2010.02079.x.CrossRefPubMed

47.

Korda J, Pfaus JG, Kellner CH, et al. Persistent genital arousal disorder (PGAD): case report of long-term symptomatic management with electroconvulsive therapy. J Sex Med. 2009;6:2901–9.CrossRefPubMed

48.

Yih J, Gagnon C, Minton J, Goldstein I. 017 Retrospective review of lumbo-sacral shockwave therapy outcomes for genito-pelvic dysesthesia/persistent genital arousal disorder. J Sex Med. 2020;17(7):227-S227.CrossRef

49.

Nazik H, Api M, Aytan H, Narin R. A new medical treatment with botulinum toxin in persistent genital arousal disorder: successful treatment of two cases. J Sex Marital Ther. 2014;40:170–4. https://doi.org/10.1080/0092623X.2013.788109.CrossRefPubMed

50.

Rubin RS, Winter AG, Minton JN, Gagno C, Goldstein I. 038 Peri-clitoral botulinum toxin as a treatment for persistent genital arousal disorder (PGAD). J Sex Med. 2017;14(6):e364–e364.CrossRef

51.

Rosenbaum TY. Physical therapy treatment of persistent genital arousal disorder during pregnancy: a case report. J Sex Med. 2010;7:1306–10. https://doi.org/10.1111/j.1743-6109.2009.01654.x.CrossRefPubMed

52.

Jones CL, Fischer JR, Hernandez SL. Sacral neuromodulation for the treatment of persistent genital arousal disorder. Obstet Gynecol. 2016;128:321–3.CrossRefPubMed

53.

Jackowich RA, Mooney KM, Hecht E, Pukall CF. Online pelvic floor group education program for women with Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia: Descriptive feasibility study. JMIR formative research. 2021;5(1):e22450–e22450.CrossRefPubMedPubMedCentral

54.

Elkins GR, Ramsey D, Yu Y. Hypnotherapy for persistent genital arousal disorder: a case study. Intl J Clin Exp Hypn. 2014;62(2):215–223. https://doi.org/10.1080/00207144.2014.869136.CrossRef

55.

Bilal AR. Treatment of persistent genital arousal disorder: Single case study. Cogent Psychology. 2020;7.

56.

Aswath M, Pandit LV, Kashyap K, Ramnath R. Persistent genital arousal disorder. Indian J Psychol Med. 2016;38(4):341–3.CrossRefPubMedPubMedCentral

57.

• Pease ER, Ziegelmann M, Vencill JA, Kok SN, Collins CS, Betcher HK. Persistent Genital Arousal Disorder (PGAD): A clinical review and case series in support of multidisciplinary management. Sex Med Rev. 2021:Jan:10(1):53–70. https://doi.org/10.1016/j.sxmr.2021.05.001. Current review of the PGAD/GPD treatment literature.

58.

• Martín-Vivar M, Villena-Moya A, Mestre-Bach G, Hurtado-Murillo F, Chiclana-Actis C. Treatments for persistent genital arousal disorder in women: a scoping review. J Sex Med. 2022:19(6):961–74. First scoping review of PGAD/GPD to be published.

59.

Kruger THC. Can pharmacotherapy help persistent genital arousal disorder? Expert Opin Pharmacother. 2018;19(15):1705–9.CrossRefPubMed

60.

Jaderek I, Lew-Starowicz M. A systematic review on mindfulness meditation–based interventions for sexual dysfunctions. J Sex Med. 2019;16(10):1581–96.CrossRefPubMed

61.

Günzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions–a systematic review of controlled clinical trials: part 2–the efficacy of psychosocial interventions for female sexual dysfunction. J Sex Med. 2012;9(12):3108–25. https://doi.org/10.1111/j.1743-6109.2012.02965.x.CrossRefPubMed

62.

Frühauf S, Gerger H, Schmidt HM, et al. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav. 2013;2013(42):915–33. https://doi.org/10.1007/s10508-012-0062-0.CrossRef

63.

van Reijn-Baggen DA, Han-Geurts IJM, Voorham-van der Zalm PJ, Pelger RCM, Hagenaars-van Miert CHAC, Laan ETM. Pelvic floor physical therapy for pelvic floor hypertonicity: a systematic review of treatment efficacy. Sex Med Rev. 2021;209–230.

64.

Rochera MB. Physiotherapy in treating sexual pain disorders in women: a systematic review. Advances in Sex Med. 2016;6:26–32. https://doi.org/10.4236/asm.2016.63004.CrossRef

65.

Morin M, Carroll MS, Bergeron S. Systematic review of the effectiveness of physical therapy modalities in women with provoked vestibulodynia. Sex Med Rev. 2017;5:295–322. https://doi.org/10.1016/j.sxmr.2017.02.003.CrossRefPubMed

66.

Berghmans B. Physiotherapy for pelvic pain and female sexual dysfunction: an untapped resource. Int Urogynecol J. 2018;29(5):631–638. https://doi.org/10.1007/s00192-017-3536-8.CrossRefPubMedPubMedCentral

67.

Morin M, Dumoulin C, Bergeron S, Myrand MH, Khaliffe S, Waddell G, et al. Randomized clinical trial of multimodal physiotherapy treatment compared to overnight lidocaine ointment in women with provoked vestibulodynia: design and methods. Contemp Clin Trials. 2016;46:52–9. https://doi.org/10.1016/j.cct.2015.11.013.CrossRefPubMed

68.

Cyr MP, Dumoulin C, Bessette P, Pina A, Gotlieb WH, Lapointe-Milot K, et al. A prospective single-arm study evaluating the effects of a multimodal physical therapy intervention on psychosexual outcomes in women with dyspareunia after gynecologic cancer. J Sex Med. 2021;18:946–54. https://doi.org/10.1016/j.jsxm.2021.02.014.CrossRefPubMed

69.

Mendes de Araujo IM, Lima Monterio TJ, Ferreira Siqueira ML. Non-pharmacological therapeutic approaches to painful sexual dysfunction in women: integrative review. BrJP 2021;4:239–44. https://doi.org/10.5935/2595-0118.20210036

70.

Goldstein AT, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: Assessment and treatment. J Sex Med. 2016;13(4):572–90.CrossRefPubMed

71.

Flanagan E, Herron KA, O’Driscoll C, Williams AC. Psychological treatment for vaginal pain: does etiology matter? A systematic review and meta-analysis. J Sex Med. 2015;12(1):3–16. https://doi.org/10.1111/jsm.12717.CrossRefPubMed

72.

Bergeron S, Khalife S, Dupuis MJ, McDuff P. A randomized clinical trial comparing group cognitive-behavioral therapy and a topical steroid for women with dyspareunia. J Consult Clin Psychol. 2016;84:259–68. https://doi.org/10.1037/ccp0000072.CrossRefPubMed

73.

Bergeron S, Vaillancourt-Moral MP, Corsini-Munt S, Steben M, Delisle I, Maryrand MH, et al. Cognitive-behavioral couple therapy versus lidocaine for provoked vestibulodynia: a randomized clinical trial. J Consult Clin Psychol. 2021;89:316–26. https://doi.org/10.1037/ccp0000631.CrossRefPubMed

74.

Zarski AC, Berking M, Ebert DD. Efficacy of internet-based guided treatment for genito-pelvic pain/penetration disorder: results of a randomized controlled trial. J Consult Clin Psychol. 2021;89:909–24. https://doi.org/10.1037/ccp0000665.CrossRefPubMed

75.

Saunders F, Vosper J, Gibson S, Jamieson R, Zelin J, Barter J, et al. Compassion focused psychosexual therapy for women who experience pain during sex. OBM Integr Complement Med. 2022;7. https://doi.org/10.21926/obm.icm.2202017.

76.

Brotto LA, Basson R, Smith KB, Driscoll M, Sadownik L. Mindfulness-based group therapy for women with provoked vestibulodynia. Mindfulness. 2015;6:417–32. https://doi.org/10.1007/s12671-013-0273-z.CrossRef

77.

Brotto L, Bergeron S. Mindfulness, and cognitive behavior therapy for provoked vestibulodynia: mediators of treatment outcome and long-term effects. J Consult Clin Psychol. 2020;88:48–64. https://doi.org/10.1037/ccp0000473.CrossRefPubMed

78.

Brotto L, Zdaniuk B, Rietchel L, Basson R, Bergeron S. Moderators of improvement from mindfulness-based vs traditional cognitive behavioral therapy for the treatment of provoked vestibulodynia. J Sex Med. 2020;17:2247–59. https://doi.org/10.1016/j.jsxm.2020.07.080.CrossRefPubMed

79.

Brotto L, Bergeron S, Zdaniuk B, Driscoll M, Grabovac A, Sadownik L, et al. A comparison of mindfulness-based therapy for the treatment of provoked vestibulodynia in a hospital clinic setting. J Sex Med. 2019;16:909–23. https://doi.org/10.1016/j.jsxm.2019.04.002.CrossRefPubMed

80.

Dunkley C, Brotto L. Psychological treatments for provoked vestibulodynia: integration of mindfulness-based and cognitive behavioral therapies. J Clin Psychol. 2016;72:637–50. https://doi.org/10.1002/jclp.22286.CrossRefPubMed

81.

Rosen NO, Dawson SJ, Brooks M, Kellogg-Spadt S. Treatment of vulvodynia: pharmacological and non-pharmacological approaches. Drugs. 2019;79(5):483–93. https://doi.org/10.1007/s40265-019-01085-1. PMID: 30847806.CrossRefPubMed

82.

Lahaie MA, Boyer SC, Amsel R, Khalifé S, Binik YM. Vaginismus: a review of the literature on the classification/diagnosis, etiology and treatment. Women’s Health. 2010;6(5):705–19.PubMed

83.

Bergeron S, Morin M, Lord MJ. Integrating pelvis floor rehabilitation and cognitive-behavioral therapy for sexual pain: what have we learned and where do we go from here? J Sex and Rel Ther. 2010;25:289–98. https://doi.org/10.1080/14681994.2010.486398.CrossRef

84.

Bergeron S, Lord MJ. The integration of pelvi-perineal re-education and cognitive-behavioural therapy in the multidisciplinary treatment of the sexual pain disorders. J Sex and Rel Ther. 2003;18(2):135–41.CrossRef

85.

Brotto LA, Goldmeier D. Mindfulness interventions for treating sexual dysfunctions: The gentle science of finding focus in a multitask world. J Sex Med. 2015;12(8):1687–9.CrossRefPubMed

86.

• Bohm-Starke N, Ramsay KW, Lytsy P, Nordgren B, Sjoberg I, Moberg K et al. Treatment of provoked vulvodynia: a systematic review. J Sex Med. 2022;19:789–808. https://doi.org/10.1016/j.jsxm.2022.02.008. Systematic review of treatments for provoked vestibulodynia.

Titel: Persistent Genital Arousal Disorder/Genitopelvic Dysesthesia: Review of the Current State of the Treatment Literature and Future Directions in Treatment
verfasst von: M. E. Mulroy
C. F. Pukall
Publikationsdatum: 07.06.2023
Verlag: Springer US
Erschienen in: Current Sexual Health Reports / Ausgabe 3/2023
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI: https://doi.org/10.1007/s11930-023-00366-x

Prescribing PDE5 Inhibitors: Best Practices, Common Practices, and Controversies

Women’s Orgasm and Its Relationship with Sexual Satisfaction and Well-being

Open Access

Sexual Health in Space: a 5-year Scoping Review

Open Access

Postpartum Sexual Function and Depression: a Review of Recent Literature

Older LGBTQ Adults and Sexual Health

Sexual Dysfunction Related to Ketamine Use: a Systematic Review

Neu im Fachgebiet Urologie

Subkutanes Pembrolizumab als Therapiealternative?

16.04.2025
NSCLC
Nachrichten

Pembrolizumab ist unter anderem beim nichtkleinzelligen Bronchialkarzinom (NSCLC) in intravenöser Form zugelassen. Eine subkutane Gabe (s.c.) könnte die Therapie angenehmer und effizienter gestalten. In einer Phase-3-Studie wurde nun untersucht, ob die s.c. Injektion in Kombination mit Chemotherapie der i.v. Therapie bei NSCLC-Erkrankten unterlegen ist.

Wie häufig entwickeln Betroffene mit einem Melanom eine weitere primäre Krebserkrankung?

14.04.2025
Melanom
Nachrichten

Menschen, die an einem malignen Melanom erkrankt sind, machen sich häufig Sorgen über das Risiko, im weiteren Verlauf erneut an Krebs zu erkranken. Eine australische Studie zeigt, dass am häufigsten ein weiteres Melanom diagnostiziert wird – gefolgt von Prostata-, Brust- und Darmkrebs.

Frauen mit HPV-Läsionen: Auch die Partner untersuchen!

11.04.2025
Sexuell übertragbare Erkrankungen
Nachrichten

Frauen, die eine durch humane Papillomviren (HPV) verursachte hochgradige zervikale intraepitheliale Neoplasie aufweisen, sollten auch ihre Männer zum Screening schicken. Denn deren Risiko für hochgradige penile HPV-Läsionen ist deutlich erhöht.

Harnsteine bei Säuglingen: Darauf ist zu achten

10.04.2025
Urolithiasis
Nachrichten

Urolithiasis bei Säuglingen und Kindern ist bislang wenig erforscht. Ein türkisches Studienteam beschreibt anhand eigener Erfahrungen den Erfolg der Behandlungsoptionen und Faktoren, die mit dem Harnsteinleiden in Zusammenhang stehen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Persistent Genital Arousal Disorder/Genitopelvic Dysesthesia: Review of the Current State of the Treatment Literature and Future Directions in Treatment

Abstract

Purpose of Review

Recent Findings

Summary

Weitere Artikel der Ausgabe 3/2023

Prescribing PDE5 Inhibitors: Best Practices, Common Practices, and Controversies

Women’s Orgasm and Its Relationship with Sexual Satisfaction and Well-being

Sexual Health in Space: a 5-year Scoping Review

Postpartum Sexual Function and Depression: a Review of Recent Literature

Older LGBTQ Adults and Sexual Health

Sexual Dysfunction Related to Ketamine Use: a Systematic Review

Neu im Fachgebiet Urologie

Subkutanes Pembrolizumab als Therapiealternative?

Wie häufig entwickeln Betroffene mit einem Melanom eine weitere primäre Krebserkrankung?

Frauen mit HPV-Läsionen: Auch die Partner untersuchen!

Harnsteine bei Säuglingen: Darauf ist zu achten

Update Urologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten